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Background: Epiregulin (EPR) is a novel member of the epidermal growth factor (EGF) family. It has been shown
to promote wound healing in oral epithelium, enhance proliferation of other epithelial tissues, and is involved in
several epithelial-related malignancies such as colorectal, lung, and bladder carcinoma. More recently, EPR transcripts
were found to be high in a study on archival oral squamous cell carcinoma (OSCC) specimens. This implies that EPR
may be responsible for the progression of OSCC. The aim of this was to elucidate the effects of EPR on (i) cell
morphological changes, (ii) cell proliferation and (iii) receptor expression of the H-series OSCC cell lines.
Methods: The clinicopathological origin and the expression of the epidermal growth factor receptor (EGFR) and
ErbB4 receptors of the H-series cell lines were initially characterised. Based on these parameters, two of the H-series cell
lines, namely H103 and H357 were selected for downstream experiments. The cell lines were treated with 1 ng/ml,
10 ng/ml, and 20 ng/ml of EPR for 24 and 48 hours in all subsequent experiments. Untreated cells acted as the control
which was used for comparison with each treated group. The cell morphological changes, cell proliferation and
receptor expression of the OSCC cell lines were evaluated using phase contrast microscopy, 5-bromo-2’-deoxy-uridine
(BrdU) assays and flow cytometry respectively. The results were compared and analysed using the student t-test.
Results: There were no appreciable morphological changes in the cells regardless of the dose of EPR tested nor
between the different timelines. There were no significant changes in cell proliferation after EPR treatment. As for
the effect of EPR on receptor expression, 20 ng/ml of EPR significantly reduced the density of EGFR expression
(p value = 0.049) in the H103 cell line after the 24-hour treatment. No other statistically significant changes were
detected.
Conclusions: The results show that EPR had no effect on the morphology and proliferativity of OSCC cells.
However, the significant decline in EGFR expression after EPR treatment suggests that EPR might play an important role
in the regulation of EGFR expression and hence OSCC progression.
Keywords: Oral squamous cell carcinoma, Epiregulin, Epidermal growth factor receptor, ErbB4Introduction
Oral cancer is the eighth most common cancer in the
world [1], with oral squamous cell carcinomas (OSCCs)
making up the majority of oral cancers [2]. Diagnosis
is often made when the cancer is in the late stages of
malignancy, and this accounts for the poor prognosis
of OSCC despite advances in treatment options and* Correspondence: dchkong@hotmail.com
1International Medical University (IMU), Bukit Jalil 57000, Kuala Lumpur,
Malaysia
Full list of author information is available at the end of the article
© 2014 Kong et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.protocols for oral cancer management [3-8]. The contrib-
utors to the poor prognosis of OSCC are probably multi-
factorial including environmental exposures especially
tobacco smoking and alcohol consumption, genetic
susceptibility [3,9], and molecular influences [10-13]
such as growth factors and their receptors.
The epidermal growth factor (EGF) family consists
of 13 polypeptide members: EGF, transforming growth
factor-alpha (TGF-α), amphiregulin (AR), heparin-binding
EGF-like growth factor (HB-EGF), betacellulin (BTC), epir-
egulin (EPR), epigen (EPG), and six neuregulins (NRGs):td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are found in the form of transmembrane pro-ligands
which are proteolytically cleaved to release the mature
soluble form which will then proceed to interact with
EGF receptors [21]. There are four types of EGF recep-
tors: epidermal growth factor receptor (EGFR), ErbB2,
ErbB3, and ErbB4. The binding of EGF ligand members
to these EGF receptors can lead to dimerisation of the
receptors which subsequently initiates downstream
intracellular signalling cascades ultimately resulting in
their mitogenic effects [14,16,22]. An array of trans-
cription factors are activated through these signalling
cascades, producing cellular proliferation, differentiation,
apoptosis, chemotaxis, and migration [23-27].
Based on previous studies, the EGF family may play a
role in OSCC progression due to its multitude of physio-
logical and malignant effects in human tissues and mice
models [28-50]. For example, a study on the saliva of OSCC
patients demonstrated raised EGF levels post-surgery,
which may indicate OSCC regeneration secondary to
tumour tissue injury thus implying a role of EGF in the
development of OSCC. In other studies, EGF and HB-EGF
were shown to promote cell migration and invasion in
OSCC cell lines via enhancement of matrix metalloprotein-
ase (MMP) activity [51,52]. The EGF family ligands – AR,
EPG, EPR, TGF-α and HB-EGF – were also shown to be
expressed at high levels in an OSCC cell line, which sug-
gests that the EGF family may play an important role in
OSCC progression [51]. Another study demonstrated that
higher levels of TGF-α was correlated with lower tumour
differentiation, incriminating that TGF-α may somehow be
responsible for OSCC differentiation or de-differentiation
[53]. Due to the paucity of studies and the limited nature of
existing studies, the relationship between the EGF family
and OSCC remains unclear and it can only be speculated
that the EGF family regulates OSCC proliferation, migra-
tion, invasion, and differentiation, based on known interac-
tions between the EGF family, the EGF receptors, and the
outcomes of their intracellular signalling cascades.
Epiregulin is one of the novel members of the EGF fam-
ily, and was initially purified from a conditioned medium
of the NIH3T3/clone T7 mouse fibroblast-derived tumour
cell line [15]. Epiregulin binds directly to EGFR and ErbB4
[54]. Activation of EGFR by EPR can lead to activation
of downstream Ras-Raf-mitogen activated protein kinase
(MAPK)-extracellular signal-regulated kinase (ERK) as
well as the phosphatidylinositol-3-kinase (PI3K)-Akt path-
ways to increase cellular proliferation [55-58]. On the
other hand, it is unclear whether activation of ErbB4 by
EPR stimulates increased cellular proliferation although
one study did show that another EGF family member,
NRG-1β, increased proliferation by coupling MAPK to
ErbB4 [59]. Physiologically, it has been shown to promote
wound healing in the oral cavity by stimulating cellularmigration of gingival epithelial and fibroblast cells, as well
as promoting the proliferation and repopulation of injured
gingival epithelium [35]. Epiregulin also stimulates pro-
liferation of keratinocytes, vascular smooth muscle cells
(VSMCs), corneal epithelium, renal proximal tubular cells
(RPTCs), and fibroblasts [55,60-62]. In terms of EPR’s
malignant potential, an up-regulation of EPR expression
was found in some human cancers such as bladder can-
cer and malignant fibrous histiocytoma (MFH) [63,64].
Additionally, EPR transcripts were shown to be expressed
in bladder, lung, kidney, colon, and epidermoid carcinoma
cell lines [65].
In 2008, Shigeishi et al. [34] showed that in archival
OSCC tissue specimens, EPR messenger ribonucleic acid
(mRNA) expression was found to be significantly greater
when compared to normal gingivae and dysplastic epi-
thelium, and this was correlated with poor patient clin-
ical outcome. These findings, together with the fact that
EPR is involved in a wide range of human cancers,
suggest that the poor clinical outcome may be caused by
the influence of EPR on tumour progression in terms of
proliferation, migration, and invasion. This has provided
some insight into the possible role of EPR in oral cancer.
In order to determine whether EPR has a potential
effect in OSCC tumour progression in vitro, the current
study reports the effect of EPR on cell morphology, cell
proliferation, and cellular expression of EGFR and ErbB4
receptors in OSCC cell lines.Results
Selection of cell lines for downstream experiments
Clinicopathological considerations
Out of the seven cell lines, H103 and H357 share similar
clinicopathological characteristics with regards to the
sex and Site (S)-Size (T)-Nodal metastasis (N)-Distant
metastasis (M)-Pathology (P) (STNMP) grades of the
patients (see Table 1) [66]. However, these two cell lines
differ with regards to the patients’ age.EGFR and ErbB4 receptors screening
Figures 1 and 2 show the flow cytometric outputs for
the EGFR and ErbB4 receptor screening. The results of
the screening are shown in Table 2.
With regards to the EGFR and ErbB4 expression pro-
files, all the H-series cell lines expressed both the EGFR
and ErbB4 receptors. However, the ErbB4 expression of
H357 was negative.
Taking the patients’ clinicopathological characteristics
as well as the presentation of the receptors into consid-
eration, the H103 and H357 cell lines were selected. The
H357 cell line was selected to serve as a negative control
in the setting of downstream experiments due to its
ErbB4 negativity.
Table 1 Clinicopathological characteristics of the H-series cell lines
Cell line Nationality Age Sex Sitea (S) Size (T) Nodal metastasis (N) Distant metastasis (M) Pathologyb (P) STNMP gradec
H103 British 32 M T < 20 - - W I
H157 British 84 M BM 20-40 + - W II
H314 British 82 M FOM 20-40 + - M II
H357 British 74 M T < 20 - - W I
H376 British 40 F FOM 20-40 + - W III
H400 British 55 F AP 20-40 - - M II
H413 British 53 F BM 20-40 - - M II
aSite: T, tongue; BM, buccal mucosa; FOM, floor of mouth; AP, alveolar process.
bPathology: W, well-differentiated; M, moderately-differentiated; P, poorly-differentiated.
cSTNMP grade: prognostic indicator for OSCC with 51.5%, 40.7%, 21.6% and 8.3% 5 year survival for patients with a stage I, II, III or IV tumours, respectively.
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H103 cell line
Figures 3A-D show the morphology of cells after 24-hour
treatment with EPR. The cell line displayed a hetero-
geneous population of small to large cells with a spindle-
like appearance. There were no differences in morphology
between the treated groups (regardless of the dose of EPR)
and the untreated control. Figures 3E-H show the morph-
ology after 48-hour treatment. The cell line also displayed
similar morphology as those after 24-hour treatment. Not
only were there no morphological changes between the
groups within each timeline, there were also no differences
between the treated groups (regardless of the dose of EPR)
and the untreated control. No differences in morphology
between the two timelines of treatment were found.
H357 cell line
Figures 4A-D show the morphology of cells after 24-hour
treatment. The cell line displayed a heterogeneous popu-
lation of small to large cells with rounded appearance.
There were no differences in morphology between the
treated groups (regardless of the dose of EPR) and the
untreated control. Figures 4E-H show the morphology
after 48-hour treatment. The cell line also displayed simi-
lar morphology as 24-hour treatment. Not only were there
no morphological changes between the groups within each
timeline, there were also no differences between the
treated groups (regardless of the dose of EPR) and the
untreated control. No differences in morphology between
the two timelines of treatment were found.
The findings showed that there were no morphological
changes in the cells after treatment with EPR.
Determination of cell proliferation
The proliferation of the OSCC cells was measured based
on (i) cell count and (ii) 5-bromo-2’-deoxy-uridine (BrdU)
assay. In order to assess any changes in cell proliferation
after EPR treatment, we compared the cell count/absorb-
ance of cells between each EPR-treated group, namely
1 ng/ml, 10 ng/ml and 20 ng/ml, with the control.(i)Proliferation based on cell count
H103 cell line
Figure 5A shows a marginal increase in cell counts com-
pared to the control, when 10 ng/ml of EPR was added to
the cell line and left for 24 hours. There were also similar
increases in cell counts when 1 ng/ml and 10 ng/ml of
EPR were added to the cell lines and left for 48 hours.
These increases however, were not statistically significant.
H357 cell line
Figure 5B shows marginal increase in cell counts com-
pared to the control in all treated groups (regardless of
the dose of EPR) when EPR was added to the cell line
and left for 24 hours. However, there were no increases
in cell counts in all treated groups (regardless of the
dose of EPR) when EPR was added to the cell line and
left for 48 hours. These increases however, were not
statistically significant.
The findings showed that there were no significant
changes in the cell counts after treatment with EPR.
(ii)Proliferation based on BrdU assay
H103 cell line
Figure 6A shows marginal increases in cell proliferation
compared to the control, when 10 ng/ml and 20 ng/ml of
EPR were added to the cell line and left for 24 and 48 hours.
These increases however, were not statistically significant.
H357 cell line
Figure 6B shows marginal increases in cell proliferation
compared to the control, when 1 ng/ml and 10 ng/ml of
EPR was added to the cell line and left for 24 hours. There
were also marginal increases in cell proliferation compared
to the control when 10 ng/ml and 20 ng/ml of EPR were
added to the cell line and left for 48 hours. These increases
however, were not statistically significant.
The findings of both the cell counts and BrdU assays
showed no significant changes after EPR treatment.
This suggests that EPR does not have an effect on cell
proliferation.
Figure 1 Flow cytometric output for the EGFR and ErbB4 receptors screening in the H103 cell line. The true percentage of cells expressing
EGFR or ErbB4 receptors were calculated by subtracting the autofluorescence of the unstained cells (B and D) from the fluorescence of the cells stained
with the anti-EGFR-FITC or anti-ErbB4-PE antibodies (C and E) respectively. A The polygonal box, R1 represents the gating of the cells based on the
forward and side scatter profiles to exclude cellular debris and doublet cells. A total of 10,000 gated events were acquired for analysis. B The
green dots within the R2 box represent the autofluorescence of unstained cells. This autofluorescence was subtracted from the fluorescence
detected in C. C The green dots within the R2 box represent the fluorescence of cells after staining with anti-EGFR-FITC antibodies. D The pink
dots within the R3 box represent the autofluorescence of unstained cells. This autofluorescence was subtracted from the fluorescence detected
in E. E The pink dots within the R3 box represent the fluorescence of cells after staining with anti-ErbB4-PE antibodies.
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Figures 7, 8, 9 and 10 show the effects of EPR on the EGFR
and ErbB4 receptors expression based on flow cytometric
outputs for the H103 cell line and for H357 cell line re-
spectively after 24- and 48-hour treatment respectively.
From these outputs, the (i) percentage of cells and (ii) dens-
ity of expression of EGFR and ErbB4 receptors were deter-
mined. In order to assess any changes in receptor
expression after EPR treatment, we compared the per-
centage of expression/mean fluorescence intensity (MFI)
of EGFR and ErbB4 between each EPR-treated group,
namely 1 ng/ml, 10 ng/ml and 20 ng/ml, with the control.(i)Percentage of cells expressing EGFR and ErbB4 receptor
H103 cell line
Figure 11A–B show decreases in the percentage of cells
expressing EGFR compared to the control in all treated
groups (regardless of the dose of EPR), when EPR was
added to the cell line and left for 24 and 48 hours. On the
other hand, Figure 11C shows increases in the percentage
of cells expressing ErbB4, when 1 ng/ml and 20 ng/ml of
EPR (but not 10 ng/ml which showed a decrease) were
added to the cell line and left for 24 hours. Similarly,
Figure 11D shows an increase in the percentage of cells
expressing ErbB4 compared to the control, when 1 ng/ml
Figure 2 Flow cytometric output for the EGFR and ErbB4 receptors screening in the other H-series cell lines. The polygonal R1 boxes in
A–F (cell lines are A H157, B H314, C H357, D H400, and E H413) represents the gating of the cells based on the forward and side scatter profiles
to exclude cellular debris and doublet cells. A total of 10,000 gated events were acquired for analysis for each cell line. Similar analyses to obtain
the true percentage of cells expressing EGFR and ErbB4 receptors were performed as per Figure 1.
Table 2 Receptor status for the H-series of cell lines
Cell line Receptor status
EGFR expression (%) Positivity ErbB4 expression (%) Positivity
H103 0.72 + 0.19 +
H157 0.91 + 0.12 +
H314 0.47 + 0.03 +
H357 2.34 + 0.00 -
H376 1.94 + 0.10 +
H400 1.84 + 0.53 +
H413 7.74 + 0.27 +
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Figure 3 Cell morphology of the H103 cell line after 24- and 48-hour treatment. A and E Untreated control. B and F Treated with 1 ηg/ml EPR.
C and G Treated with 10 ηg/ml EPR. D and H Treated with 20 ηg/ml EPR. The cells were assessed under low magnification (20x) phase contrast
microscopy for any changes in morphology between the treated groups and the untreated control within each timeline, between the treated
groups and between the two timelines of treatment. The cells were assessed in terms of size, shape, nuclear and cytoplasmic changes.
Kong et al. Cancer Cell International 2014, 14:65 Page 6 of 22
http://www.cancerci.com/content/14/1/65of EPR (but not 10 ng/ml and 20 ng/ml which showed
decreases) was added to the cell line and left for 48 hours.
These changes however, were not statistically significant.
H357 cell line
Figure 12A–B show increases in the percentage of
cells expressing EGFR compared to the control, when
1 ng/ml of EPR (but not 10 ng/ml and 20 ng/ml which
showed decreases) was added to the cell line and left
for 24 and 48 hours. On the other hand, Figure 12C–Dshow increases in the percentage of cells expressing ErbB4
compared to the control, when 1 ng/ml of EPR (but not
10 ng/ml and 20 ng/ml which showed decreases) was
added to the cell line and left for 24 and 48 hours. These
changes however, were not statistically significant.
(ii)Density of receptors: EGFR and ErbB4
H103 cell line
Figure 13A–B show decreases in the density of EGFR
expression in all treated groups (regardless of the dose
Figure 4 Cell morphology of the H357 cell line after 24- and 48-hour treatment. A and E Untreated control. B and F Treated with 1 ηg/ml
EPR. C and G Treated with 10 ηg/ml EPR. D and H Treated with 20 ηg/ml EPR. The cells were assessed under low magnification (20x) phase
contrast microscopy for any changes in morphology between the treated groups and the untreated control within each timeline, between the
treated groups and between the two timelines of treatment. The cells were assessed in terms of size, shape, nuclear and cytoplasmic changes.
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to the cell line and left for 24 and 48 hours. A significant
decrease in the density of EGFR expression was detected
(p-value = 0.049) when 20 ng/ml of EPR was added
to the cell line and left for 24 hours as shown in
Figure 13A. Figure 13C shows an increase in the density
of ErbB4 expression compared to the control, when
1 ng/ml of EPR (but not 10 ng/ml and 20 ng/ml which
showed decreases) was added to the cell line and left for
24 hours. On the other hand, Figure 13D shows in-
creases in the density of ErbB4 expression in all treated
groups (regardless of the dose of EPR) compared to thecontrol, when EPR was added to the cell line and left for
48 hours. These changes other than the one in Figure 13A
however, were not statistically significant.
H357 cell line
Figure 14A–B show decreases in the density of EGFR
expression in all treated groups (regardless of the dose
of EPR) compared to the control, when EPR was added
to the cell line and left for 24 and 48 hours. On the
other hand, Figure 14C shows an increase in the density
of ErbB4 expression compared to the control, when
20 ng/ml of EPR (but not 1 ng/ml and 10 ng/ml which
Figure 5 Cell counts. A H103 cell line after 24- and 48-hour treatment. B H357 cell line after 24- and 48-hour treatment. Bars represent mean ±
standard error of mean of a triplicate of experiments. The findings showed no statistically significant differences in cell counts after treatment
with EPR.
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for 24 hours. However, Figure 14D shows decreases in
the density of ErbB4 expression in all treated groups
(regardless of the dose of EPR) compared to the con-
trol, when EPR was added to the cell line and left for
48 hours. These changes however, were not statistically
significant.
Discussion
Up to 90% of oral cancers are OSCCs. Oral cancer is
mostly diagnosed by the conventional method of oral
inspection and palpation [67-69] but most oral cancers
are already in their late stages at the time of detection,
resulting in higher patient morbidity and mortality. A
great amount of research is being put into identifying
suitable biomarkers for earlier detection of oral can-
cers but existing or newly identified biomarkers are yetto be validated clinically. In this aspect, EPR cannot be
ignored as a potential candidate for use as a diagnostic
marker and prognosticator although this requires
further studies into its role in OSCC and its clinical
implications.
Epiregulin was particularly selected for investigation
following the recent report by Shigeishi et al. [34] who
studied EPR mRNA expression in archival material and
showed a significant correlation between higher EPR
mRNA and poorer survival in OSCC patients. Their
study indicated that EPR could play a role in OSCC pro-
gression. No other studies have investigated the role of
EPR in OSCC cell lines. Thus, the present study has pro-
vided an insight into the possible role of EPR in the
growth and characteristics of OSCC cells in cell lines, by
observing and assessing the changes in cell morphology
and proliferation. We investigated whether EPR exerted
Figure 6 BrdU assay. A H103 cell line after 24- and 48-hour treatment. B H357 cell line after 24- and 48-hour treatment. Bars represent mean ±
standard error of mean of a triplicate of experiments. The findings showed no statistically significant differences in absorbance after treatment
with EPR.
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i.e. EGFR or ErbB4, since EPR has been known to bind
directly to these receptors [54]. In order to achieve
that, it was therefore important to establish whether
the H-series cell lines express these receptors through
screening.
Prime et al. [66] showed through immuno-staining
and radio-ligand binding assays that all the H-series cell
lines expressed EGFR. The results of the present study
confirm the positivity of EGFR expression in all the
H-series cell lines. In addition to EGFR, the present
study also demonstrated that almost all the H-series
cell lines expressed ErbB4. The H357 ErbB4 expression
was negative due to very minimal detection of its
expression (percentage of ErbB4 expression < 0.01%).
The present study is the first to demonstrate theexpression of ErbB4 in the H-series OSCC cell lines
and would be useful for future studies using this cell
line.
The ability of EPR to cause morphological changes in
OSCC (especially in dedifferentiation) is clinically import-
ant. Oral squamous cell carcinomas are mostly well-
differentiated and moderately- to well-differentiated [2,70]
with lower differentiation associated with increased
tumour aggressiveness. Poor patient outcome in terms
of tumour recurrence, metastasis, and worst disease-free
survival is associated with OSCC tumours that are poorly-
differentiated [71-73]. In the present study, treatment with
EPR produced no changes in the morphology of the H103
and H357 cell lines. This may be due to the tissue
expression of EPR predominating in the macrophages
and placenta but not particularly so in other tissues
Figure 7 Flow cytometric output for the EGFR and ErbB4 receptors expression after 24-hour EPR treatment in the H103 cell line.
The outputs for the untreated control are represented by B and F. C and G, D and H, and E and I represent outputs for cells treated with 1 ηg/ml,
10 ηg/ml, and 20 ηg/ml of EPR respectively. The true percentage of cells and the density of expression of the EGFR or ErbB4 receptors were
calculated by subtracting the autofluorescence of the unstained cells (not shown) from the fluorescence of the cells stained with the anti-EGFR-FITC or
anti-ErbB4-PE antibodies (B–I) respectively. A The R1 polygonal box represents the gating of the cells based on the forward and side scatter
profiles to exclude cellular debris and doublet cells. A total of 10,000 gated events were acquired for analysis. B–E The green dots within the R2
boxes represent the fluorescence of cells after staining with anti-EGFR-FITC antibodies. F–I The pink dots within the R3 boxes represent the
fluorescence of cells after staining with anti-ErbB4-PE antibodies.
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EPR lies mainly in reproductive and immune physiology.
Although other studies [57,60,74] have shown that EPRinduced morphological changes in ovarian granulosa cells,
epidermal keratinocytes and vascular smooth muscle cells,





Figure 8 Flow cytometric output for the EGFR and ErbB4 receptors expression after 48-hour EPR treatment in the H103 cell line.
The outputs for the untreated control are represented by B and F. C and G, D and H, and E and I represent outputs for cells treated with 1 ηg/ml,
10 ηg/ml, and 20 ηg/ml of EPR respectively. The true percentage of cells and the density of expression of the EGFR or ErbB4 receptors were calculated
by subtracting the autofluorescence of the unstained cells (not shown) from the fluorescence of the cells stained with the anti-EGFR-FITC or
anti-ErbB4-PE antibodies (B–I) respectively. A The R1 polygonal box represents the gating of the cells based on the forward and side scatter profiles
to exclude cellular debris and doublet cells. A total of 10,000 gated events were acquired for analysis. B–E The green dots within the R2 boxes represent
the fluorescence of cells after staining with anti-EGFR-FITC antibodies. F–I The pink dots within the R3 boxes represent the fluorescence of cells after
staining with anti-ErbB4-PE antibodies.







Figure 9 Flow cytometric output for the EGFR and ErbB4 receptors expression after 24-hour EPR treatment in the H357 cell line.
The outputs for the untreated control are represented by B and F. C and G, D and H, and E and I represent outputs for cells treated with 1 ηg/ml,
10 ηg/ml, and 20 ηg/ml of EPR respectively. The true percentage of cells and the density of expression of the EGFR or ErbB4 receptors were calculated
by subtracting the autofluorescence of the unstained cells (not shown) from the fluorescence of the cells stained with the anti-EGFR-FITC or
anti-ErbB4-PE antibodies (B–I) respectively. A The R1 polygonal box represents the gating of the cells based on the forward and side scatter
profiles to exclude cellular debris and doublet cells. A total of 10, 000 gated events were acquired for analysis. B–E The green dots within the
R2 boxes represent the fluorescence of cells after staining with anti-EGFR-FITC antibodies. F–I The pink dots within the R3 boxes represent the
fluorescence of cells after staining with anti-ErbB4-PE antibodies.







Figure 10 Flow cytometric output for the EGFR and ErbB4 receptors expression after 48-hour EPR treatment in the H357 cell line.
The outputs for the untreated control are represented by B and F. C and G, D and H, and E and I represent outputs for cells treated with 1 ηg/ml,
10 ηg/ml, and 20 ηg/ml of EPR respectively. The true percentage of cells and the density of expression of the EGFR or ErbB4 receptors were
calculated by subtracting the autofluorescence of the unstained cells (not shown) from the fluorescence of the cells stained with the anti-EGFR-FITC or
anti-ErbB4-PE antibodies (B–I) respectively. A The R1 polygonal box represents the gating of the cells based on the forward and side scatter profiles to
exclude cellular debris and doublet cells. A total of 10,000 gated events were acquired for analysis. B–E The green dots within the R2 boxes represent
the fluorescence of cells after staining with anti-EGFR-FITC antibodies. F–I The pink dots within the R3 boxes represent the fluorescence of cells
after staining with anti-ErbB4-PE antibodies.
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Figure 11 Percentage of cells expressing EGFR and ErbB4 receptors in the H103 cell line. The percentage of cells expressing EGFR treated
for A 24 hours and B 48 hours, and the percentage of cells expressing ErbB4 treated for C 24 hours and D 48 hours.
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ology of the H103 and H357 cell lines may be due to the
short treatment periods of these cell lines with EPR over
24 and 48 hours. Previous studies have used cells from
primary cultures and therefore the findings in the present
study are not comparable. Once successfully cultivated
in vitro, cells from primary cultures become cell strains
which possess characteristics not seen in cell lines such as
maintenance of the diploid karyotype, retention of histoty-
pical differentiation, and having similar cell morphology
to primary tissue [75,76]. If this fact holds true in the
H103 and H357 cell lines, it could be that they have lost
their ability to differentiate. Last but not least, the absence
of interaction with other cell types such as neighbouring
fibroblasts as per in vivo could directly or indirectly medi-
ate the effects on EPR on OSCC cell differentiation as
demonstrated in studies of other tissues [77,78].
The proliferativity of OSCCs has been linked to higher
tumour-node-metastasis (TNM) grading, poorer prognosis,
and tumour differentiation with poorer differentiation
associated with higher proliferativity as shown in acytokinetic study in OSCCs [79]. An immunohisto-
chemical study on archival OSCC specimens established
an association between higher OSCC proliferative index
with older patients, late clinical staging, larger tumour
size, nodal metastasis, and distant metastasis [80]. Shir-
akata et al. [60] and Morita et al. [62] demonstrated
that EPR cause a logarithmic increase in the number of
cells in human epidermal keratinocytes and human cor-
neal epithelial cells and these increases were dose-
dependent. Zhuang et al. [55] reported that EPR enhanced
proliferation of rabbit RPTCs. These studies demonstrated
that an optimal EPR dose of 10 ng/ml with an effective
dose up to 20 ng/ml was essential for enhanced prolifera-
tion. Bringing together the results of the cell counts and
BrdU proliferation assays, the present study demonstrated
that EPR did stimulate marginal increases in cell prolifera-
tion although these findings were not statistically signifi-
cant. This phenomenon could be due to several reasons,
the first being that the concentrations of EPR of ≤
20 ng/ml used may be too low to elicit a significant
cellular response in OSCC cell lines. Sasaki et al. [81]
Figure 12 Percentage of cells expressing EGFR and ErbB4 receptors in the H357 cell line. The percentage of cells expressing EGFR treated
for A 24 hours and B 48 hours, and the percentage of cells expressing ErbB4 treated for C 24 hours and D 48 hours.
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cantly promote proliferation of rabbit gastric cancer
cells and pancreatic cancer cell lines respectively at con-
centrations up to 100 ng/ml. The marginal increases
may also be attributed to the different cell types i.e. epi-
dermal keratinocytes or RPTCs which respond differ-
ently to EPR compared to OSCC cells.
Other than differential responses, the short treatment
periods of 24 and 48 hours could be the other contribut-
ing factors for the marginal increases in cell prolifera-
tion. Similar studies by Morita et al. [62], Zhang et al.
[83], and Lindvall et al. [84] employed longer treatment
periods of between six to twelve days. Previous studies
have also used different techniques to measure cell pro-
liferation such as protein and dye reduction assays which
have different sensitivities and specificities. This study
has demonstrated that EPR may have the potential for
promoting greater OSCC proliferation if EPR concentra-
tions or treatment periods were increased.
Binding of EGF family ligand(s) and activation of their
respective receptor(s) have been reported to lead to theinternalisation of the ligand-receptor complex prior to
lysosomal targeting and degradation (reviewed in refer-
ence 25). This process will subsequently reduce the cell
surface expression of the affected receptor(s). With this,
it is plausible that EPR could also down-regulate the
expression of EGFR and ErbB4. In the present study, the
only significant reduction detected was the density of
EGFR expression in the H103 cell line which occurred at
the EPR concentration of 20 ng/ml after 24 hours of treat-
ment. This finding concurred with Citri and Yarden’s
model of receptor regulation [25]. This significant re-
duction could also be explained by EGFR homo-dimer
formation which occurs preferentially at high ligand
concentrations and which are internalised more effi-
ciently than EGFR hetero-dimers [85]. However, it is yet
unclear why within the same cell line there was no sig-
nificant reduction in the density of EGFR expression
after the 48-hour treatment. It could be that EPR is
rapidly and extensively depleted by EGFR uptake with
subsequent internalisation and degradation, resulting in
reduced concentration of EPR after 48 hours [14,64].
Figure 13 Density of EGFR and ErbB4 receptors in the H103 cell line. The density of EGFR receptors treated for A 24 hours and B 48 hours,
and the density of ErbB4 receptors treated for C 24 hours and D 48 hours. *Represents significant reduction in density of EGFR receptors (student
t-test, p-value = 0.049).
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unable to induce any significant down-regulation of EGFR.
The minimal changes in EGFR expression may be due
to the interference of EGFR internalisation [86] and the
associated limitation in the cellular components mediat-
ing receptor down-regulation, thus making it a saturable
process at the level of internalisation [87] as well as at
the level of targeting of ligand-receptor complexes to
lysosomes for degradation [88]. In other words, the
capacity of the intracellular molecular components me-
diating receptor down-regulation defines the maximum
amount of active receptors that can be down-regulated
and degraded at any one time, regardless of the number
of ligand-activated EGFR. In addition, there may also
be a significant extent of receptor hetero-dimerisation
which slowed post-endocytic trafficking of internalised
receptors. Lenferink et al. [89] and Worthylake et al. [90]
demonstrated that EGFR-ErbB2 hetero-dimers slowed
internalisation and targeting of ligand-receptor complexes
to lysosomes. It must be noted that EPR possess thecapacity to activate almost all possible hetero-dimeric
EGF receptor complexes [56]. In the present study, the
ErbB2 receptor was not investigated and the possibility
of its influence on regulation of EGFR expression after
EPR stimulation thus, cannot be excluded. Lenferink
et al. [89] demonstrated that EGF stimulation rapidly
diminishes EGFR expression in contrast to TGF-α which
caused reappearance of EGFR presumably due to recycling
of endocytosed receptors. These studies indicate that
hetero-dimerisation with another EGF family receptor
slows the down-regulation of EGFR expression and the
type of EGF family ligand that binds to EGFR also dic-
tates the regulation of EGFR expression.
There were no significant changes in the ErbB4 expres-
sion after EPR treatment in both the H103 and H357 cell
lines in the present study. This confirms that the H357 cell
line is truly negative for ErbB4, verifying the results of the
initial screening for ErbB4 expression. Evidence has shown
that ErbB4 receptor is deficient in several components of
the down-regulatory system and that it behaves rather
Figure 14 Density of EGFR and ErbB4 receptors in the H357 cell line. The density of EGFR receptors treated for A 24 hours and B 48 hours,
and the density of ErbB4 receptors treated for C 24 hours and D 48 hours.
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reviewed that unlike EGFR, ErbB4 does not possess the
capacity to directly recruit certain intracellular elements
involved with receptor internalisation and degradation.
Several studies postulated that regulation of ErbB4
expression is ligand-independent [91,92] and may ex-
plain why EPR did not induce any significant changes
in ErbB4 expression in the present study. The non-
significant changes in EGFR and ErbB4 expression after
EPR stimulation in both H103 and H357 cell lines may
be due to the rate of receptor recycling exceeding that
of receptor internalisation. In addition, intracellular
EGFR and ErbB4 receptors stored within vesicles in theTable 3 Summary of the clinicopathological characteristics an
Cell line Age STNMP gradea EG
H103 32 I Significantly
24
H357 74 I No s
aSTNMP grade: prognostic indicator for OSCC with 51.5%, 40.7%, 21.6% and 8.3% 5cellular cytoplasm might have been directed to the cell
surface during this recycling process resulting in a sur-
plus expression of receptors in cells treated with EPR
compared to the untreated control [25].
Based on previous studies, there is cumulative evidence
that the aggressiveness of OSCC is related to the patients’
age i.e. the younger the patient, the worse the prognosis
[93-96]. Interestingly, in the present study, the 5-year
survival of the patients as dictated by the STNMP grade
is the same in both the H103 and H357 cell lines despite
the age differences (Table 3).
In terms of clinical implications of EGFR expression
on patient survival, a higher EGFR expression wasd receptor expression of the H103 and H357 cell lines
FR expression ErbB4 expression
reduced in density after
hour treatment.
No significant changes.
ignificant changes. No significant changes.
Confirmed to be negative for ErbB4.
-year survival for patients with a stage I, II, III or IV tumours, respectively.
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This association was frequently found in breast [97,98]
and colorectal cancers [99,100]. A study by Thomas
et al. [101] on archival OSCC specimens of young
adults aged between 18 to 40 years showed that low
EGFR expression conferred a 100% five-year survival
rate while high EGFR expression reduced the survival
rate to 81.1%. Upon this basis, it can be inferred that
the good survival rate in the younger patient (from
which the H103 cell line originated) (Table 3) could
possibly be attributed to the ability of the EGFR receptor
to be significantly down-regulated upon ligand binding.
There was however, no correlation between ErbB4
expression and OSCC prognosis. This concurred with
findings from several other similar studies looking at
other epithelial cancers [102-104]. This shows that
ErbB4 might not be an independent predictor for
survival of OSCC patients. Despite all these studies, it
must be noted that there have been conflicting reports
on the correlation between the age of the patient with
survival, and the association between survival and
EGFR and ErbB4 expression [99,100,105-112]. In one
study, higher expression of ErbB4 has been linked to
better prognosis [113].
Conclusions
Epiregulin could significantly decrease (down-regulate)
EGFR expression but not the ErbB4 receptor in OSCC
cell lines. However, it does not significantly affect the
cell morphology in OSCC cell lines nor does it signifi-
cantly enhance OSCC cell proliferation.
Whilst it is possible that when EPR binds to EGFR, it
induces down-regulation of this receptor which leads to
signal attenuation for differentiation and proliferation of
OSCC cells as seen in the H103 cell line. This attenu-
ation in differentiation and proliferation could explain
why there were no significant changes in cellular morph-
ology and proliferation in the present study. With refer-
ence to the clinicopathological origins of the H103 and
H357 cell lines, it is also possible that the good survival
rate for the younger patient may be attributed to this
phenomenon. The ability of EPR to significantly down-
regulate EGFR in the H103 cell line after 24 hours of
treatment but not after 48 hours suggests that signal
attenuation may be achieved by other means. As for the
H357 cell line, no significant changes in morphology
and proliferation were seen, suggesting that there is
an inherent heterogeneity in biological responses even
between cells (OSCC) of the same type despite no
significant changes in EGFR expression. On the other
hand, the ErbB4 receptor most likely did not play a
role in OSCC cellular differentiation and proliferation.
The results of the expression of ErbB4 after EPR
treatment in the present study substantiate the factthat the regulation of ErbB4 expression may be ligand-
independent.
Despite the previous and present investigations, it
must be noted that the level of EGFR and ErbB4 recep-
tors expression might not imply a cause-and-effect rela-
tionship with OSCC progression.
Materials and methods
Cell culture and material
Seven OSCC cells lines, namely H103, H157, H314, H357,
H376, H400, and H413 were obtained for the screening of
suitable cell lines to be incorporated in the studies. All cell
lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) nutrient mixture F-12 Ham supplemented with
10% foetal bovine serum (FBS), 0.5 μg/ml hydrocortisone,
and 1% of penicillin-streptomycin at 37°C in 5% carbon
dioxide (CO2) tissue culture incubator. The cells were
split at a 1:3 ratio and passaged every three days upon
confluence. The cell lines were treated for one cycle with
2 μg/ml of gentamicin replacing penicillin-streptomycin,
added directly into complete medium. Thereafter, the
cells were maintained in antibiotics-free medium for all
downstream experiments.
Selection of cell lines for downstream experiments
All the H-series cell lines were characterised based on
the clinicopathological characteristics of the patients
where the cell lines were derived from, and also on their
receptors, particularly EGFR and ErbB4. Both characte-
risations were done simultaneously for the selection of
suitable cell lines for downstream experiments in the
present study.
Clinicopathological considerations
The clinicopathological characteristics of the patients
from which the H-series cell lines were derived are
shown in Table 1. [66]. The criteria for selecting the cell
lines were age, sex, and STNMP grade of the patients.
EGFR and ErbB4 receptors screening
For surface receptor analysis of all cell lines, cells were tryp-
sinised using 0.25% of trypsin-ethylenediaminetetraacetic
acid (EDTA) for 5 minutes and subsequently inhibited with
complete culture medium. The cells (1 × 106) were washed
with phosphate-buffered saline (PBS) and blocked with
10% of FBS in PBS for 10 minutes prior to incubation
with antibodies. The incubation of the cells with 10% of
FBS in PBS functioned as a blocker to inhibit the unspe-
cific Fc receptors of the cells. Subsequently, the cells
were incubated with anti-EGFR-fluorescein (FITC) and
anti-ErbB4-phycoerythrin (PE) antibodies respectively
in staining buffer containing 1% of bovine serum albu-
min (BSA) in PBS for 30 minutes at 4°C. The cells were
washed twice with PBS to remove excess antibodies and
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cytometry was performed using a FACSCalibur flow
cytometer and data obtained was analysed using the
CellQuest Pro software. Cells were gated on the basis of
forward and side scatter profile to exclude cellular deb-
ris and doublet cells. A total of 10, 000 events were
taken for analysis. A positive (+) EGFR or ErbB4 expres-
sion is defined as a percentage expression of ≥ 0.01%
and a negative (−) expression is defined as a percentage
expression of < 0.01%.
Epiregulin treatment
Two cells lines, H103 and H357, were cultured over-
night in complete culture medium before EPR treat-
ment. The test group of cells were treated with 1 ng/ml,
10 ng/ml or 20 ng/ml of EPR each time, added into the
complete culture medium for 24 and 48 hours respect-
ively. The control group contained complete culture
medium without addition of EPR.
Morphology observation
Control and treated cells were observed under low
magnification (20×) phase contrast microscopy for the
identification of the cells’ morphology and morphology
changes (if any) upon EPR treatment. The morphological
characteristics assessed include size, shape, nuclear and
cytoplasmic changes.
Cell count for viability
Cell counts for control and treated cells were performed
using standard trypan blue exclusion method using a
haemocytometer. The experiments were conducted in trip-
licates and performed thrice to confirm the reproducibility.
BrdU proliferation assay
Cells were plated into 96-well plates in 200 μl of
complete culture medium. The plates were then incu-
bated overnight at 37°C in 5% CO2. The medium was
then removed and exchanged with culture medium con-
taining the various concentrations of EPR. Control cells
were maintained in complete culture medium.
Cell proliferation was monitored at 24 and 48 hours
after commencement of EPR treatment by adding 20 μl
of BrdU labelling solution into each well of the 96-well
plate and incubated for another 4 hours at 37°C in 5%
CO2. Following incubation, the cells were washed twice
with complete culture medium. The cells were then
fixed with 70% ethanol in 0.5 M hydrochloric acid (HCl)
for 30 minutes at −20°C. The cells were then washed
thrice with complete medium before incubation with
100 μl of nucleases for 30 minutes at 37°C in a water
bath. The cells were subsequently washed thrice with
complete medium and incubated with 100 μl of anti-
BrdU-peroxidase (POD), Fab fragments for 30 minutesat 37°C. The cells were finally washed thrice with PBS
and incubated with 100 μl of peroxidase substrate at
room temperature for 30 minutes prior to analysis. The
plate was read on a microplate reader at a wavelength of
405 nm. The experiments were conducted in triplicates
and performed thrice to confirm the reproducibility.Surface receptor analysis for EGFR and ErbB4
The surface receptor analysis was performed using the
methods as described under ‘EGFR and ErbB4 receptors
screening’. The MFI of EGFR and ErbB4 was used to
determine the expression density of these receptors (the
amount of receptors over the number of gated cells) on
the treated cells when compared to the control cells. For
the percentage of expression and MFI changes after
treatment with EPR, 1 × 106 of EPR-treated and control
cells were obtained using the methods as described earlier.
The quantitative flow cytometric analysis for the percentage
of expression of anti-EGFR- and anti-ErbB4-labelled cells
was calculated by counting labelled cells which exceeded
the upper limit of the auto-fluorescence of unlabelled cells.
The presented MFI of labelled cells was calculated by sub-
tracting the auto-fluorescence intensity of the unlabelled
cells within the same sample. The experiments were con-
ducted in triplicates and performed thrice to confirm the
reproducibility.Statistical analysis
All data were represented as mean values ± standard error
of mean. Results were analysed using SPSS version 18. Be-
cause the number of samples is only three in the control
group as well as each of the EPR-treated group, namely
1 ng/ml, 10 ng/ml and 20 ng/ml, we believe that the sample
is normally distributed and hence the student t-test was
used to analyse any two independent groups within the
study. The level of significance for all comparisons was set
at 0.05 and statistically significant results (p < 0.05) were
highlighted.
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